N
Google TrendPOSICIONES DE ATLÉTICO DE MADRID CONTRA MANCHESTER UNITED (5000+) — Atlético 2 - 0 Manchester United: resumen, goles y resultado de la Champions League
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:posiciones de atlético de madrid contra manchester united5000+devils vs red wings2000+lioness season 35000+luis díaz200+halle berry child custody hearing200+lamine yamal5000+thélyson orélien500+abdulrahman alfozan500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Convergent Therapeutics a" (30 stories)

Top Headline Story

Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lead StoryBusiness Wireworld
Jun 1

Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC)

<a href="https://news.google.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?oc=5" target="_blank">Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC)</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
5000+23m ago

posiciones de atlético de madrid contra manchester united

Atlético 2 - 0 Manchester United: resumen, goles y resultado de la Champions League

Filter stories
2000+23m ago

devils vs red wings

Devils at Red Wings projected lineups

Filter stories
5000+23m ago

lioness season 3

Thank Zoe Saldaña for ‘Lioness’ Season 3’s Perfect Cliff-Hanger

Filter stories
200+33m ago

luis díaz

Max Eberl knows Luis Díaz will start scoring again for Bayern Munich

Filter stories

Search Results for "Convergent Therapeutics a"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Convergent Therapeutics names Michael Rossi to board of directors
AuntMinniegeneral

Convergent Therapeutics names Michael Rossi to board of directors

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxPWnc2ZHJZQWl4YUo5RjRkUUpRYUlmZk54SDJrRmw5SVZ0aTVNVVR1aVJHWFBuVEpOUW5rdklCcS1RU21SZllzUU9BaWt1S0FkSXhOVjVzTjZxbmx0N0lYWjJzMGpTXzFacWpCaG1RVlFpMzFfTU5aVHdJWFQ3bXdOWU4xODk1LUhQeG45MlVoVUluMFpaVG9MLTZSX2tBWE5zODJPOUtOR3hnZlBKZjhobGhoQWU2LUhUUzQxVnp1azFBTWMtZXRlNHdlQk9kZXJZRlZGc1FXSlBpUExUR1NTaXFOV2s2a0E3TW80?oc=5" target="_blank">Convergent Therapeutics names Michael Rossi to board of directors</a>  <font color="#6f6f6f">AuntMinnie</font>

Read Full StoryMore like this
Convergent Therapeutics Appoints Andrew Davis Chief Business and Strategy Officer
citybizgeneral

Convergent Therapeutics Appoints Andrew Davis Chief Business and Strategy Officer

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQZWNyVEJQQVBvR3RJanZKcEcybDlvVUdqSG55bS0wZl9NeWFtQmswb0hvN3VVNUdOY0l4WFFSZzUtUHVOZzRaa3UwbkUtdUQzdlVnY2plMkJYOTFVbDU0US1Kdmlzc2pva1M2RzhxdDgxOWpXS3YwX3NPSWtwZjY4cEQySjROT3dXaFpXNW1qWTBMQWxTNWZrTV93UlZFVFRhX08xeERfZVU1VDNfd1hkNnJvQTl2b3dRa0dzZA?oc=5" target="_blank">Convergent Therapeutics Appoints Andrew Davis Chief Business and Strategy Officer</a>  <font color="#6f6f6f">citybiz</font>

Read Full StoryMore like this
Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026
Business Wiregeneral

Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026

<a href="https://news.google.com/rss/articles/CBMi4gJBVV95cUxQa2RsUUlwXy01R3FSS2NkYW9kMkpQWDNzeDM0eml1YktuanFwX0Q3YWJzN3dENUlMOU81Y3FNUmVaWkF5aDYxMDdtSWdjTzJtSldlMEFGb1VEa2dvYnpUZUt5ZnNWcEdtN05FeVJZVTNlM2otSUI5WS0tUGlOSlZDUmRId3pBNVEyNEY4ckJFMVluRVhIOEx1SWZ6QVZPbUtYQlpSa3d4b3FUVEhiVmRxMHZCczZhTzlFZndHNmRRYU5YX0Z1OS1ZdUtlbjVxU0tlVlY3MXRwU3NzMVhKb29mVl9NNWcyZzNqbmVULTlwWjk2dTVGaXkwVTlTSndfLWpyNTJkbjZVT3h2Q0pwQTI0TVVUbm1DVnpFMEZJRmxRdy0tMU0zbEZJY2Q2b0ZqeTAyZm5WVjlWMVJobGlzckVIRm9DelBTUVZMYjE1aW5sZmloZldiLUl2a2cxSE9qUTBwOFE?oc=5" target="_blank">Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Philip Kantoff Recognized Among The 100 Most Influential CEOs in Oncology in 2025
Oncodailygeneral

Philip Kantoff Recognized Among The 100 Most Influential CEOs in Oncology in 2025

<a href="https://news.google.com/rss/articles/CBMiY0FVX3lxTFAtUzQ5dzFyQlhGUlQxMVAwYzA0ZFJjekxLOFZtb2hOVGp5clF5OUFvQ3pZTHBydHBkcl9TZUdOS0YtcWREWDNZT2w2TTVOUDJ2ZlBCeE1obmlaOW5aalVKTGdMUQ?oc=5" target="_blank">Philip Kantoff Recognized Among The 100 Most Influential CEOs in Oncology in 2025</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
After Pluvicto: Alpha radiopharma and prostate cancer
pharmaphorumgeneral

After Pluvicto: Alpha radiopharma and prostate cancer

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxOME45Qm10eGdKSE5MQm5KeDBpeDd3dkZXbE5SWmlhX1Q5RnNnN044S3VscXBOQ2pTNW1nZ2FCQm1SajBxOHhDVTluMVRBSVd4Ym1fYWRmNHhoV2Rvc05HSy0tcFlKRXkzMF9lX25YaFM1Y2hKdmFfYkEtYXJLVFBFSklCNUJfSlpNU0VSVW5kUQ?oc=5" target="_blank">After Pluvicto: Alpha radiopharma and prostate cancer</a>  <font color="#6f6f6f">pharmaphorum</font>

Read Full StoryMore like this
Convergent Therapeutics and NorthStar Medical Radioisotopes Announce Expanded Partnership to Support Convergent's Late-Stage Alpha-Emitting Radioantibody Program
BioSpaceworld

Convergent Therapeutics and NorthStar Medical Radioisotopes Announce Expanded Partnership to Support Convergent's Late-Stage Alpha-Emitting Radioantibody Program

<a href="https://news.google.com/rss/articles/CBMipwJBVV95cUxNNjNqS1p3SjFxYVZUTDE3RFNGTGRjbmFzLUgxRnNOeFlabkNJU0stOUJQaHcxZnlQTUk1bXJRMFlPSllpd0hXOTR5am1kVGFRTkhxdE4yaDd6Q3ZEd3ltNjFJelJSLVZlWlp3eUZLam5WeTR0dHJ0M1hONGMxajdNVFE3WXYzTUpvUlFxUjZsMlg3eExiUmFMOThZTXVUS1oyMjlLdWdvNnNEbEF2ZTA2X2RrRGQ2bW1PeUlvSjNLaU9XT2RJc1hKYUpVemhkOXNWRm9UTnpWZTJDMGczcERrODVoay1WTnNoNkp0TnlPUlVLMTNHOTFrTkFrUE9WNmJxQ3hKS2VwZHBDdGFQa2tHVWdjRzJsd3lfZWRiUHdRdUFJLUx4UFZr?oc=5" target="_blank">Convergent Therapeutics and NorthStar Medical Radioisotopes Announce Expanded Partnership to Support Convergent's Late-Stage Alpha-Emitting Radioantibody Program</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Convergent Therapeutics Names Andrew Davis Chief Business and Strategy Officer
Business Wiregeneral

Convergent Therapeutics Names Andrew Davis Chief Business and Strategy Officer

<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxNZlNlYUtFVXhSUUtfVUQ4YzlIY0xxZFNZN2ROSnRvSVRIYW1IVWxmaV9nU3JDWmlTbmVySkVKWk1RS25xck1JVWl4U3ZfQ19hazdtU0lmVnFEaVozRGphanFtcTM0akszakFMWU9vdG16VXFLNDFpNGczbUdlU3lhUHlna0lmUUZsbFFCTk1MUDFXOFhFVG1xdF9CQ3J3M2tUNUNZczBLakVpOVVKdU5iMkJ0Rk5BT0NkQXBld1VEcVBfc1RwWGJqWDVjM0poWWpS?oc=5" target="_blank">Convergent Therapeutics Names Andrew Davis Chief Business and Strategy Officer</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Convergent raises $90M to develop its radiopharmaceutical for prostate cancer
BioPharma Divetech

Convergent raises $90M to develop its radiopharmaceutical for prostate cancer

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOOHpySU1yeW1YQzRDNDF3LVdvVEJsbDRHZVBHenpCakQ2LVRLaVA0SnFGWmpWdThiZWJrNHNEQjRuM1VWREJ1X3dLODFyYkVQTWViOW11WFEyTE44SWlZcDA0YjBKczZKZXdGRXVBdnpVT1lnUVBCbTN6SE05elljU3ZxQnhVT2ZseFhyRWQxR1VrT21LOFg3YmxYbjNkQQ?oc=5" target="_blank">Convergent raises $90M to develop its radiopharmaceutical for prostate cancer</a>  <font color="#6f6f6f">BioPharma Dive</font>

Read Full StoryMore like this
Radiopharmaceuticals in Prostate Cancer Part 4A: Endpoints, Immunotherapy, and Future Directions - Michael Morris & Rana McKay
UroTodayworld

Radiopharmaceuticals in Prostate Cancer Part 4A: Endpoints, Immunotherapy, and Future Directions - Michael Morris & Rana McKay

<a href="https://news.google.com/rss/articles/CBMixAJBVV95cUxQaUl0ekZMczFBblBjRXNzNEczNTdfUEp1QTFIZUdETHFYVmY4czIzbFlFZmNnYUpGeWx3T3VMV1kzSjdLanAtQ1loczgyNFRNU2NkYjBLRGFCWlZRNjhjcTFYMldKZGM1cmV6cW1xNUROS3YydnU4VGdDQnRDa1Y1ODVUbVNWaVJBSGVOdHdVOFNPdERoVS1aalc1RWVNeHQxVjRBMExERnM0UUM1cjZYTXQzNDEtMGtUaks0UmlMMHB4M2R1TTRNd3h2b0tNZEhmQTVYellyRlBqMEJqWERNUU9Gd2V5LU9Hd3h6S3RhVmRjd0hIM1BtWndvUW96b29QRXNTM0c0R3N0djhFQ3JFVWhEbmRoT2Z3NW05QTdmaE9PLXhxMVdlVFRUWV9mckxxYzMwVTZ1czZTZVdkcExRZjNWMnM?oc=5" target="_blank">Radiopharmaceuticals in Prostate Cancer Part 4A: Endpoints, Immunotherapy, and Future Directions - Michael Morris & Rana McKay</a>  <font color="#6f6f6f">UroToday</font>

Read Full StoryMore like this
Radiopharmaceutical company Convergent closes series A to the tune of $90M
Fierce Biotechworld

Radiopharmaceutical company Convergent closes series A to the tune of $90M

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPMnd5aFRPdVp5WERmZHp3dVlRV1pNT3RCbU1jbVVvTW1hRXpIekllSGNYV3hTZm9hV2NXVGtGSFJHVERfWVdWTHpKclg4a2doMWtDNExIdGhTcmQyazdmM2NxTDdyLVktUXdHTVNpTFlvTHNrMmxMNFg3LV9YNUV1UC1rTVp5RVdacEp2emExa09ySjJOc0N4Y2FsUGs4Sk1C?oc=5" target="_blank">Radiopharmaceutical company Convergent closes series A to the tune of $90M</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
Convergent Therapeutics: $40 Million (Series A Extension) Secured From Novo
Pulse 2.0general

Convergent Therapeutics: $40 Million (Series A Extension) Secured From Novo

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNSG1kSVJwT1NZRUp5VXR6RVk5UHh3eS1fOXl6d3Y1Tlk5Rm1uMkZ3QjRlYWxySGlDVTFlUmRQX0N6dW1XZ2ZRQzN1NEVvY2FtVmFzNHJJNjNBYkhfb29sNVB5YmFDaXlGRGI1NjF1RXBGdU5mRk9RNWF0UVdabmhld1BjdzN3RkRKc09tQTZHSHVoRGNNdWfSAZsBQVVfeXFMTnRXU002MmJsNzJybkZsdXJfOU9EZTU4OEZ2emUyT0hjR2lSdkg0Ql90ZDBleXNHSzlYclh2bkVwcnZXeS0zb2FXQWg2R215S0pGWlp0RUZDaGZ2SVhzMnhDajNlX09aZDcxTWNQWmI0VUk3OWdnaENTTlc0MmFmX2RuWThLZEcwdGMzZkZyeV9TSm4zXzNhaDhHNU0?oc=5" target="_blank">Convergent Therapeutics: $40 Million (Series A Extension) Secured From Novo</a>  <font color="#6f6f6f">Pulse 2.0</font>

Read Full StoryMore like this
Ac-225 rosopatamab tetraxetan shows promising activity in Lu-PSMA–pretreated mCRPC
Urology Timesgeneral

Ac-225 rosopatamab tetraxetan shows promising activity in Lu-PSMA–pretreated mCRPC

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNdElnMWdGMGtzUzFRYU43NXFpUkhYRUhiTTloNlBuazNKb1lHZjVTcDZnZmlmUS05dy1Qb2VPZ2g5aThRRENCSFlGYlEya0c3eXgyOGE5RXhCZk9xWHV1WG80bGp1QWdVMXoydjZXY3RQQ2dsb0gwRXFrOTZ2VVlTeUI3Mk45MG1FTk1XclVSZXg5UVFLRjZRNHFoSWFiT1dvWkh4c3BEYV9LMVRKYk8wbkoxRlpqU28?oc=5" target="_blank">Ac-225 rosopatamab tetraxetan shows promising activity in Lu-PSMA–pretreated mCRPC</a>  <font color="#6f6f6f">Urology Times</font>

Read Full StoryMore like this
Radiopharmaceutical shows promise in post-Pluvicto setting
STATgeneral

Radiopharmaceutical shows promise in post-Pluvicto setting

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNbUlzUDJjSDA5amI1NUNXdHBUbTd3Rnh2UkZJMkdqWmdWNFNHbl9yR3dHcTlMRHJ4amJ4MHJCNmZjc2pOYVVUQnRkZjdrQmxvZzB3ZllQR3ltcHhfM19SOWVnSlpVSlBqVGZzWkVvWmthU3RaeWVjMFdpejgyWWlDN1dteGY2Z0w3WldLbkhRNFhTWVA4OXhpbFVLYkJjbHk4QWc?oc=5" target="_blank">Radiopharmaceutical shows promise in post-Pluvicto setting</a>  <font color="#6f6f6f">STAT</font>

Read Full StoryMore like this
Convergent Therapeutics to Present Phase 2 Data for CONV01-α in Lu-PSMA pretreated Metastatic Castration-Resistant Prostate Cancer Patients at the 2026 ASCO Annual Meeting
Business Wiregeneral

Convergent Therapeutics to Present Phase 2 Data for CONV01-α in Lu-PSMA pretreated Metastatic Castration-Resistant Prostate Cancer Patients at the 2026 ASCO Annual Meeting

<a href="https://news.google.com/rss/articles/CBMiywJBVV95cUxOTGFkN2dqMkxpM3hjT0NIUzlrX3RtVzJZNURhOTBNRWRSRTFSeXZxZUk0NDMwNXo3SUE0eGJoT3BfMHh2ZzVwMHdMTXlaazhod1JVZlIxbndyRE1ueGR4SmhEZVFON0hjMFJ0bHJsMkVGZmwyVTA2ZlZ4R3d4SlJFRDlKSTQ2U2U5SXJrdk9xUE1wWkdxQ3JVWnhHNzVYdUk3bmw4NkVWb0lMQmkxSHcwdzZHQWlWb2tzcVNRUzZ2UkMzSWNBa0hUa1R1OWdubFg5dUJQSUJ5MDB1MGZYRUc5TnVEeVdncXdmUnp1QlplV29jRUh2bzcyZ1BvNWVJNlp4c0d6YVc5b0luX1EyY2VBMWJJd01tTVVDRUJKTWE3bXNtUGNwSnFDSG80QVJsMWZIR0YwTTd0NTlTRnBGaktRVFF1WTgxd1NsbXlr?oc=5" target="_blank">Convergent Therapeutics to Present Phase 2 Data for CONV01-α in Lu-PSMA pretreated Metastatic Castration-Resistant Prostate Cancer Patients at the 2026 ASCO Annual Meeting</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
The promise of radiopharmaceuticals smacks into safety concerns
STATgeneral

The promise of radiopharmaceuticals smacks into safety concerns

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPWmUwSl80RS1JTUZ5aWs0V0JTbVBrcU45RjU3SUE0UjN2Uy1WT1B6aFc3X2lTYTh3YUktLU9ZamR0ODF5RnlrMUkzX2pqQWRsQ3ZlSk9sTEJ5MGVSVDdxTEVOZEo5QnplZ1gwY3poZEc0UFN5NEw4T0JsTUI2cnNCQjJIWDZTQmtFcHZ5MW5yeFNCSVIwN3c?oc=5" target="_blank">The promise of radiopharmaceuticals smacks into safety concerns</a>  <font color="#6f6f6f">STAT</font>

Read Full StoryMore like this
Convergent Therapeutics Appoints Radiopharmaceutical Industry Veteran Michael Rossi to its Board of Directors
Business Wiregeneral

Convergent Therapeutics Appoints Radiopharmaceutical Industry Veteran Michael Rossi to its Board of Directors

<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxPRHdBdkotaE5HSDdXS29udGhKU0lxLU41bHhScXJVMVlETjl3aFhkNC1UQkl5V3dweWRGYkF0TjdxM2VIQUkyamUzSmZkODY1U0hDNHJTTGNIYTBQc2hVUWZmaGEyMU5LaDdNX1hkdHlxQ3hmeWVjdnVKX1J5Zi1Qa1FtcWR0TUw0dWNRZnFhZmZuSVFsUjFRd1p5OG1OYjVfZS1rUnBjU0xHbzlDT2ZjRkdrT2I5NDBmdFNzcU54WG9wR0FncDYwV3NlMS1sRWQ2LUtVdkpuYVMtRkQ4Rzl6a2NoTkNuMWhjVWNxQzM4VXc1d0l2LUcxT1JR?oc=5" target="_blank">Convergent Therapeutics Appoints Radiopharmaceutical Industry Veteran Michael Rossi to its Board of Directors</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
The Brave New World of Radiotherapeutics
BioSpaceworld

The Brave New World of Radiotherapeutics

<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxOQmpmM3BVcjd5Ynk4ZWtCZkZyWUVkYVRrZldGX1RhQ0pyM0Zmb3ZNOVhOaVQwWGl2OHdXUkFZdUlUazgzWk44el9oemhYbnB5R085NUtfMUxKaUdHS1dYQ0RVMlRLSmE1cURqcl9tOFlkT240TC0ybldtUDlsQkdtai1OS2kxeEpWQ1E?oc=5" target="_blank">The Brave New World of Radiotherapeutics</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Convergent Therapeutics Appoints Elizabeth L. Montgomery Chief People Officer
Business Wiregeneral

Convergent Therapeutics Appoints Elizabeth L. Montgomery Chief People Officer

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNbzREY0ZUSGFzYmRiZms5c2ZReU01aDlUaTI0RFRxaE1Gc0Z2M18yZVcwN0RXNVgxbHpIVjhZMU0xM2NDRXFpdnZqbXpYNDZSa1U5bXB3cjdrUDFOb2FRU3VZV2JWbXVpczRGT1pSZW9RUU11ZjlzV0oyZ19YbTZYcnZzVmFTSHgtQVRFU2h5eWdmazVlRTliZWhWN2hsR3hqYkhRUVVJandrZmlMTGkxdEtyeEZJejMwdF9tck51bUFKYXRMR3lTRllfV2dCNDg?oc=5" target="_blank">Convergent Therapeutics Appoints Elizabeth L. Montgomery Chief People Officer</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Convergent Therapeutics Appoints Barbara Duncan to Board of Directors
citybizworld

Convergent Therapeutics Appoints Barbara Duncan to Board of Directors

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNVXYzVUJiNjdwMU5lTU9lSW5IZmYta3ZJUVAtblZDMzRoX1c5aVdaSlFvc212SUNaTUdaNVVsLTdobmJZYjhJbDRuTDFpSjg5TEk2WVJ2aVZmVnZFSXBMM0tGR25JSHN6d1dJNXBzQndoS0wyMnJBZmJHMXpiZE1xRXZUdE1CSnNBRGZoa05ELXJQR1lhTzdFVGVzWFJDNWZMek5Pc1RQbkZCMVF5?oc=5" target="_blank">Convergent Therapeutics Appoints Barbara Duncan to Board of Directors</a>  <font color="#6f6f6f">citybiz</font>

Read Full StoryMore like this
New Radiopharmaceutical Shows Antitumor Activity in Patients with Advanced Prostate Cancer
WCM Newsroomgeneral

New Radiopharmaceutical Shows Antitumor Activity in Patients with Advanced Prostate Cancer

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOZVV5Ym9xSEQtRUNqaFUwZTVPZjRUVEdGMjVtTi1KNVdZUVZOblVEQzg1Y1E3Z00xQWp6VUFpUUhJcVJpRmhMUHN2UTNkeG15ZUF3TjF5Wm42RlNyTmZKMFdNMjY2Y3lUS1h4Y1d4OFJSdkxheUF0eHZtN0loRHVGRWwzTXlqQ3lGZktTRV9hLWxvQm96Z09tcTl5YTZ3TDFUeGlJaDhER1FMNks5Z2VWc1hMMl9kQ3hod0pUX3dQeURfNUdGdkE?oc=5" target="_blank">New Radiopharmaceutical Shows Antitumor Activity in Patients with Advanced Prostate Cancer</a>  <font color="#6f6f6f">WCM Newsroom</font>

Read Full StoryMore like this
Fractionated 225Ac–J591 shows early activity, preserved QOL in mCRPC
Urology Timesgeneral

Fractionated 225Ac–J591 shows early activity, preserved QOL in mCRPC

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPclhBZXB5UjcteTgyNEVDUmxYbjlQMm9HMnpCQVFodkdkZ3hJdUhXbndXMVhpbUxEZTJDc0xITWNlX3I4ZEFMTW5QVHZRakxlVzhWakpQVTNkTm9jNTZINDFqcUFWMTJUZGZQdXVyVEJqczlUd2M2RWNaWWpiNElZYjRjR2NhSE5DQ0FYalA5NFZzYTlyblExeTFuaWFjM0lKUlU0?oc=5" target="_blank">Fractionated 225Ac–J591 shows early activity, preserved QOL in mCRPC</a>  <font color="#6f6f6f">Urology Times</font>

Read Full StoryMore like this
Convergent Therapeutics Closes $90 Million Series A Financing
citybizgeneral

Convergent Therapeutics Closes $90 Million Series A Financing

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPbG1jWWlfVUkzeE8tLTJvOElxRkZrejgzTGVtYjBMWHAweS1BUlpVMEJUSTh0YXJfU0dwalVBcGpsOXRvVGRzU2xHREZFVVNKN1p6dW5FMlRaMUZQTjgzM0QxaEpxYW1mVHJ6RFJSYXRHRHRJNFNlams1cE9QOTFmNm1zVGpfcGRhUWRjemZmelhVSDg1Q00zbnFsZ0hTUDZv?oc=5" target="_blank">Convergent Therapeutics Closes $90 Million Series A Financing</a>  <font color="#6f6f6f">citybiz</font>

Read Full StoryMore like this
Convergent Therapeutics Appoints Philip Kantoff, M.D. as CEO
citybizgeneral

Convergent Therapeutics Appoints Philip Kantoff, M.D. as CEO

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPSU9YbjVQd0ZVdHVEWGRoanlhVkRjOGNVZFdqRWlMLXdaWDNXN0p3V2hRYlhELXB0bU81YWExWTN5N0o1WE5DNGtlSDRVYXRibktwb3EyeDkwZXFnZE81MmlQZ05WMDFOb0JucW9WVTdkaTRXbV9RQUhuOVpYcDBzSmlNRUs5MndpZ0FhSUppNy1VSTAxUVZHYnRKbm5BQQ?oc=5" target="_blank">Convergent Therapeutics Appoints Philip Kantoff, M.D. as CEO</a>  <font color="#6f6f6f">citybiz</font>

Read Full StoryMore like this
Radioligand Therapies Market Set for Significant Growth by 2034, Driven by Rising Cancer Burden and Targeted Radiopharmaceutical Innovation | DelveInsight
PR Newswiremarkets

Radioligand Therapies Market Set for Significant Growth by 2034, Driven by Rising Cancer Burden and Targeted Radiopharmaceutical Innovation | DelveInsight

<a href="https://news.google.com/rss/articles/CBMisgJBVV95cUxQbEN5WWhIR0psYXlsLTJONFJPeVJia1Y4X1h1eVdrbUVpdkJxTHVDWlRHcjNFOTkwcklLcGo4ZjBRSHZZSG90Z3llRVdXdFJUeDltUkFqc1Q0Z25IYkdsQk9ESEZ3MFF4YnFkaWR2MF9ILVg2QXcwYkx5NDg5RGhHN0ZPaXA4QnFTZkpOb3VzTy1qSkVXRjc4ek1rQUdvOW9RQjZOSF9JWjdTeUJVM2l3clJvTGt4NmxZQjRrdnZzZ2dMUkREcndlMW5MVzBiSXdFQk9tNm1TQXRMd05VT0JBRE5NVFI0bm5aQkpzX3R5MXNTMW5hd0R3N3ZLa3oxOVBxZ2pLbHpaU1oxTExEaE1tSzlNRW53aEtwbXJ1QUVMMlBSUV9xanRGa1hZSG8yRkJnYWc?oc=5" target="_blank">Radioligand Therapies Market Set for Significant Growth by 2034, Driven by Rising Cancer Burden and Targeted Radiopharmaceutical Innovation | DelveInsight</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
AACR: Philip Kantoff Discusses Convergent’s Unique Path to Treating Prostate Cancer
BioSpaceworld

AACR: Philip Kantoff Discusses Convergent’s Unique Path to Treating Prostate Cancer

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxPRmxvWWNzZG5GcnFlcjdHNG5rT0M3cEQxTnQ5dEwyLW1wUnlJSkFqZk95a2hrV3NQQllIaXFXTWpXSFhRRmd6cE4wajU2eHFNRGtxa0VHTXNnbG5CSFh5RFZDWXdnSzR2bndLd3JHc21tTVRLR1hfSFZLaG5EMGRlSmxuWjcwLUNQNmRFaWZKLUpMSlV5RXZheF8wRzF1LTN4MDFJeF96N29uTE85NnhN?oc=5" target="_blank">AACR: Philip Kantoff Discusses Convergent’s Unique Path to Treating Prostate Cancer</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Up and down the ladder: The latest comings and goings
STATgeneral

Up and down the ladder: The latest comings and goings

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOU1Vod192ck9vSHlqMjJJc1YtNlRaNDZNMjdLUGtFNWIxTzY3c0RfQzhTcUo5WU05VWdQdHRtMlhERk9qNWY0dlh5MjBmcWNlOHBYLXVBTWFOS01FcjBVUGNrRldXdWVQTzk1dldCSmRYM1lIb1ZJcUJhUGVJaWZTWEN5ZFdQbFlYbHdDZmhFbXJfcDFZMkF4U3VMOXZRZlBGUTBSSjdjQVpUTUJSeTU0?oc=5" target="_blank">Up and down the ladder: The latest comings and goings</a>  <font color="#6f6f6f">STAT</font>

Read Full StoryMore like this
Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology
CancerNetworkgeneral

Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNTFNYWHhkUXh0bVZuQm9WcURLLTJGTHg0WWM5SVdJVkUycDNha2JxSzJvX0NMYU5vcUpqbVN5SGV4ZVd2a2hzMlNuNUVmVktmYVU0aEhPamZud1MwUHBMUURfNVcxZmtZNzBORVJEU21GVjBrclV5aS1pYUo1SWgwbVlDWE9LNmFSUWljV1l4Zzg2THNTbU9zcExyalBzZDB6SzZnSlYwSW51QjVUSDFNdDZuQUhDYnBuSlVZMWFRQlA1N2lZUTluX2s0QXVkZklicmVZSQ?oc=5" target="_blank">Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Jones Nauseef: I begin as Senior Medical Director at Convergent Therapeutics
Oncodailygeneral

Jones Nauseef: I begin as Senior Medical Director at Convergent Therapeutics

<a href="https://news.google.com/rss/articles/CBMiR0FVX3lxTE9TNnVLLTdJT2RIbi1waUpfNkdVU1dVX29qVmE0Nk56OWJWeVc1MDRmNUpmcE1UYUtRUTJ5QU1EODJHaEplWEln?oc=5" target="_blank">Jones Nauseef: I begin as Senior Medical Director at Convergent Therapeutics</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
FDA clears IND for 225Ac-J591 in advanced prostate cancer
Urology Timesgeneral

FDA clears IND for 225Ac-J591 in advanced prostate cancer

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNYVh6WUJXOEVxVHZ6QVRFR3NyQVljRXkwT0UwdmFMYzhKMXFBZndyZzg2WkpLY1lIdUUyN2FqU096Q3RyT205QmxaX1ZweDZMbFMwZksxRmJWNHlrc0lMMjZzblJuQWhVeF9iaG1GZmtqeXpMUURtTWowVzBQck1ocVdSMHZ6VlhxXzJjNVpXMVhveDd6U1E?oc=5" target="_blank">FDA clears IND for 225Ac-J591 in advanced prostate cancer</a>  <font color="#6f6f6f">Urology Times</font>

Read Full StoryMore like this
"Convergent Therapeutics a" — Live Google News Trends & Headlines